Omeros stock: MarketBeat lists November 12 earnings for Omeros stock

Published on 10/22/2026 at 21:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MarketBeat estimates Q3 revenue at USD 37.28 million for November 12 after market close. Omeros stock costs EUR 14.88 on October 22, 2026.

Reporting date and valuation

Omeros is expected to report third-quarter results on November 12, 2026.
MarketBeat estimates third-quarter revenue at USD 37.28 million.
Omeros stock costs EUR 14.88 at Lang & Schwarz on October 22, 2026 at 9:49 p.m. CEST.
Omeros traded at a trailing P/E ratio of 9.79 on October 22, 2026.

OMER, US6821431029, Illustration mit AI erstellt.

Omeros Corporation (ISIN US6821431029) is expected to report third-quarter 2026 results on November 12, 2026, after market close, according to MarketBeat on October 21, 2026. The report date gives investors a defined checkpoint after a volatile month for the biotechnology company. Omeros was trading at EUR 14.88 at Lang & Schwarz on October 22, 2026 at 9:49 p.m. CEST.

November 12 carries the next test

MarketBeat estimates third-quarter revenue at USD 37.28 million and consensus earnings per share at USD 0.03. The same page lists prior-year earnings per share of minus USD 0.19, giving the November report a clear comparison point. The date is an estimate rather than a confirmed company announcement.

Stock remains below the yearly high

On Nasdaq, Omeros was at USD 16.85 on October 22, 2026 at 3:57 p.m. EDT. The stock's 52-week range was USD 6.24 to USD 21.24, placing the quote 20.67 percent below the high. Market capitalization stood at USD 1.2 billion, while volume reached 522,598 shares.

Valuation and analyst view

Omeros traded at a trailing P/E ratio of 9.79 on October 22, 2026. On October 14, Investing.com reported that Cantor Fitzgerald reiterated an Overweight rating and a USD 22.00 price target. That target is 30.56 percent above the USD 16.85 Nasdaq quote from October 22, 2026.

Comparison with peers

As of October 22, 2026, the Nasdaq quote showed Omeros up 3.63 percent, with a P/E ratio of 9.79 and market capitalization of USD 1.2 billion.

Omeros (Nasdaq, USD): up 3.63 percent, P/E 9.79, market capitalization USD 1.2 billion
Bristol-Myers Squibb (NYSE, USD): up 3.24 percent, P/E 13.90, market capitalization USD 128.9 billion
Regeneron Pharmaceuticals (Nasdaq, USD): up 1.70 percent, P/E 20.26, market capitalization USD 84.4 billion

Euro quote and U.S. valuation

At Lang & Schwarz, Omeros was trading at EUR 14.88 on October 22, 2026 at 9:49 p.m. CEST. The euro quote provides the German trading perspective, while the Nasdaq valuation and November 12 reporting date remain the key reference points for the stock.

The further course of trading is shown by the continuously updated real-time quote of Omeros stock.